Skip to content

Serum/Plasma Immunoassay for Anti-GP210 Antibodies (Screening)

Published: August 9, 2026Updated: August 16, 2026

This blood test measures antibodies against a protein called GP210, which may be linked to certain autoimmune conditions or connective tissue disorders. It is often used as part of a broader evaluation.

Quick summary

["This test helps identify potential autoimmune responses to GP210, aiding diagnosis or monitoring of related health conditions."]

Medically reviewed by WellAlly Editorial TeamLast reviewed August 16, 2026Editorial policy

Key facts at a glance

LOINC
106055-7
Short code
SP100 and GP210 Ab.IgG pnl SerPl
Synonyms
SP100 and GP210 Ab.IgG pnl SerPl
Category
chemistry
Sample
serum
Container
Red-top tube (SST)
Units
N/A
Fasting
false
Population
adult
Sex
all
Age range
18–65 years
CPT
82784
Specimen volume
5 mL
Stability
Room temperature: 4h, Refrigerated: 24h, Frozen: 7d
Hemolysis max
500
Lipemia max
1000
Icterus max
500
TAT
4–24 hours
Order
routine

Why This Test Might Be Ordered

Your healthcare provider may recommend this test if you have symptoms suggestive of autoimmune diseases, such as joint pain, fatigue, or skin rashes, or if you have a family history of connective tissue disorders. It may also be used in research or specialized clinical settings to assess immune responses to specific proteins.

What to Expect Before the Test

No special preparation is typically needed. You may have a small needle inserted into your arm to draw blood. If you are on blood thinners, inform your provider beforehand.

What the Results Mean

Positive results suggest the presence of antibodies against GP210, which could indicate an immune response. However, further testing and clinical correlation are needed to determine if this is related to a specific condition. Results alone do not diagnose a disease.

Common Conditions Monitored

While GP210 antibodies are not as commonly associated with well-known conditions as others (e.g., rheumatoid arthritis), they may be studied in research for connective tissue disorders or autoimmune diseases like systemic lupus erythematosus (SLE) or scleroderma.

Clinical interpretation

How abnormal results are interpreted and what conditions they suggest.

Clinical Significance: Understanding the Role of GP210 Antibodies

Short name

GP210 Antibody Test (Screen)

Frequently asked questions

What are the typical reference ranges for this test?
Reference ranges can vary by lab and may not be widely standardized for GP210 antibodies. Your results will be interpreted in the context of your clinical symptoms and overall health. Always discuss findings with your healthcare provider.
Can this test be used to diagnose autoimmune diseases?
No, this test alone cannot diagnose an autoimmune disease. It may be part of a broader diagnostic evaluation, including physical exams, other blood tests, and clinical assessments to identify potential conditions.
How often should I get this test if I have a history of autoimmune conditions?
Frequency depends on your healthcare provider’s recommendations. They will tailor follow-up based on your symptoms, test results, and ongoing medical needs. Regular monitoring may be necessary if this test is part of your ongoing care plan.
  1. 1
  2. 2
  3. 3

Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy